United Therapeutics UTHR
NASDAQ UTHR
$503.78 +5.81 (+1.17%)
As of: Sep 9, 2026 · 12:43 PM EDT

United Therapeutics (UTHR) Deferred Taxes (2009 - 2026)

United Therapeutics' (UTHR) quarterly Deferred Taxes came in at $25.7 million in Q2 2026, down 0.77% quarter-over-quarter from $25.9 million in Q1 2026.

Analysis

United Therapeutics (UTHR) Deferred Taxes (2009 - 2026) Analysis & Trends

United Therapeutics has disclosed Deferred Taxes across 5 years of filings, most recently posting $25.7 million for Q2 2026.

  • In Q2 2026, Deferred Taxes changed N/A year-over-year to $25.7 million; the TTM figure through Jun 2026 stood at $51.6 million (down 15.9% YoY), while the FY2025 annual figure was $97.7 million, up 252.42% from the prior year.
  • Deferred Taxes came in at $25.7 million for Q2 2026 at United Therapeutics, down from $25.9 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $25.9 million in Q1 2026 to a low of $25.7 million in Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Deferred Taxes (Qtr)
1 Johnson & Johnson 642.97 Bn 622.21 Bn 17.26 Bn -479.00 Mn
2 AbbVie 441.24 Bn 434.67 Bn 12.70 Bn -195.00 Mn
3 Merck 364.65 Bn 357.51 Bn 12.21 Bn -544.00 Mn
4 Novartis Ag 266.30 Bn 258.61 Bn 11.24 Bn -
5 Pfizer 158.95 Bn 147.25 Bn 10.94 Bn -1.32 Bn
6 Sanofi 52.43 Bn 45.05 Bn 10.79 Bn -
7 Revolution Medicines 44.29 Bn 44.29 Bn - -
8 Incyte 25.27 Bn 20.73 Bn 1.57 Bn 115.62 Mn
9 United Therapeutics 21.44 Bn 18.78 Bn 683.80 Mn 25.70 Mn
10 Neurocrine Biosciences 15.52 Bn 15.13 Bn 935.80 Mn -25.30 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 25.70 Mn
Mar 31, 2026 25.90 Mn
Sep 30, 2012 30.38 Mn
Jun 30, 2012 30.97 Mn
Mar 31, 2012 33.18 Mn
Sep 30, 2011 19.23 Mn
Jun 30, 2011 35.72 Mn
Mar 31, 2011 10.44 Mn
Dec 31, 2010 -5.04 Mn
Sep 30, 2010 18.00 Mn
Jun 30, 2010 19.21 Mn
Mar 31, 2010 9.75 Mn
Dec 31, 2009 -1.75 Mn
Sep 30, 2009 -2.89 Mn